ASCP Corner: Decision Making and Antipsychotic Medication Treatment for Youth With Autism Spectrum Disorders: Applying Guidelines in the Real World
J Clin Psychiatry 2013;74(10):1022-1024
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, wehave provided for your benefit the first 3 sentences of the fulltext.
Autism spectrum disorder (ASD) is a diagnosis that is characterized by varying degrees of (1) impairment in social reciprocity, (2) impairment in social communication,and (3) repetitive, restrictive, stereotyped patterns of interests, activities, and behaviors. While ASD prevalence varies across regions, recent prevalence rates range from 1:88 children in the United States to 1:160 children worldwide.
Currently, only 2 atypical antipsychotics, risperidone (in 5- to 16-year-olds) and aripiprazole (in 6- to 17-year-olds),are approved by the US Food and Drug Administration (FDA) for treatment of significant irritability (aggression toward others, deliberate self-injuriousness, temper tantrums, and labile moods) associated with ASD.